The Dual Inhibition of SYK & JAK Kinases for the Treatment of Skin & Complex Inflammatory Conditions

Time: 11:40 am
day: Day Two


  • Addressing novel treatments in Chronic Hand Eczema as therapy gusacitinib, a dual SYK/JAK inhibitor, advances to phase 3 clinical development.
  • Evaluating additional role of TYK2 and SYK in epithelial cell/keratinocyte function
  • Detailing further potential in dermatologic and immunologic condition